ArticlePloS one2016
Impact of Azithromycin on the Quorum Sensing-Controlled Proteome of Pseudomonas aeruginosa.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 50 citations in OpenAlex.
- Innovative Approaches to Combat Antimicrobial Resistance: A Review of Emerging Therapies and Technologies.Probiotics and antimicrobial proteins · 2026Review
- Pathogenicity and virulence ofVirulence · 2025Review
- Azithromycin represses evolution of ceftazidime/avibactam resistance by translational repression ofJournal of bacteriology · 2025Article
- Innovative application of ceftriaxone as a quorum sensing inhibitor in Pseudomonas aeruginosa.Scientific reports · 2025Article
- Increased susceptibility to azithromycin of Pseudomonas aeruginosa biofilms using RPMI 1640 testing media.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2024Article
- Therapeutic Potential of an Azithromycin-Colistin Combination against XDRAntibiotics (Basel, Switzerland) · 2023Article
- Effect of quorum quenchers on virulence factors production and quorum sensing signalling pathway of non-mucoid, mucoid, and heavily mucoid Pseudomonas aeruginosa.World journal of microbiology & biotechnology · 2022Article
- Screening strategies for quorum sensing inhibitors in combating bacterial infections.Journal of pharmaceutical analysis · 2022Review
- Article
- Sub-Inhibitory Antibiotic Exposure and Virulence inAntibiotics (Basel, Switzerland) · 2021Review
- 5-Fluorouracil blocks quorum-sensing of biofilm-embedded methicillin-resistant Staphylococcus aureus in mice.Nucleic acids research · 2021Article
- Quantitative mapping of mRNA 3' ends in Pseudomonas aeruginosa reveals a pervasive role for premature 3' end formation in response to azithromycin.PLoS genetics · 2021Article
- Dynamic Adaptive Response ofAntibiotics (Basel, Switzerland) · 2021Article
- Azithromycin Exhibits Activity AgainstFrontiers in microbiology · 2021Article
- Could Azithromycin Be Part ofFrontiers in microbiology · 2021Review
- Quorum Sensing Inhibiting Activity of Cefoperazone and Its Metallic Derivatives onFrontiers in cellular and infection microbiology · 2021Article
- Identification of novel targets of azithromycin activity againstProceedings of the National Academy of Sciences of the United States of America · 2020Article
- Comparative evaluation of the effect of different growth media on in vitro sensitivity to azithromycin in multi-drug resistant Pseudomonas aeruginosa isolated from cystic fibrosis patients.Antimicrobial resistance and infection control · 2020Article
- Plant-Derived Inhibitors of AHL-Mediated Quorum Sensing in Bacteria: Modes of Action.International journal of molecular sciences · 2019Review
- In Vivo Proteome of Pseudomonas aeruginosa in Airways of Cystic Fibrosis Patients.Journal of proteome research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
The macrolide antibiotic, azithromycin (AZM), has been reported to improve the clinical outcome of cystic fibrosis patients, many of whom are chronically-infected with Pseudomonas aeruginosa. However, the highest clinically-achievable concentrations of this drug are well-below the minimum inhibitory concentration for P. aeruginosa, raising the question of why AZM exhibits therapeutic activity. One possibility that has been raised by earlier studies is that AZM inhibits quorum sensing (QS) by P. aeruginosa. To explicitly test this hypothesis the changes brought about by AZM treatment need to be compared with those associated with specific QS mutants grown alongside in the same growth medium, but this has not been done. In this work, we used quantitative 2D-difference gel electrophoresis and 1H-NMR spectroscopy footprint analysis to examine whether a range of clinically-relevant AZM concentrations elicited proteomic and metabolomic changes in wild-type cultures that were similar to those seen in cultures of defined QS mutants. Consistent with earlier reports, over half of the AZM-induced spot changes on the 2D gels were found to affect QS-regulated proteins. However, AZM modulated very few protein spots overall (compared with QS) and collectively, these modulated proteins comprised only a small fraction (12-13%) of the global QS regulon. We conclude that AZM perturbs a sub-regulon of the QS system but does not block QS per se. Reinforcing this notion, we further show that AZM is capable of attenuating virulence factor production in another Gram-negative species that secretes copious quantities of exoenzymes (Serratia marcescens), even in the absence of a functional QS system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.